We can’t show the full text here under this license. Use the link below to read it at the source.
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
Tirzepatide, a medicine targeting two hormones, in managing Type 2 diabetes: Results from the SURPASS trials
AI simplified
Abstract
is a novel dual GIP/GLP-1 receptor agonist formulated as a synthetic peptide containing 39 amino acids.
- Co-infusion of GLP-1 and GIP results in a significantly increased insulin response and glucagonostatic response compared to separate administration.
- Tirzepatide has shown potent glucose-lowering effects and weight loss in pre-clinical and phase 1 and 2 clinical trials.
- Adverse effects of tirzepatide are comparable to those of established GLP-1 receptor agonists.
- The long-term efficacy, safety, and cardiovascular outcomes of tirzepatide will be evaluated in the SURPASS phase 3 clinical trial programme.
AI simplified
Key numbers
−2.4%
Reduction
Maximum reduction observed with 15 mg in clinical trials.
−11.3 kg
Weight Loss
Maximum weight loss achieved in clinical trials.
12,500
Trial Participants
Participants involved in the SURPASS-CVOT trial.